ALZHEIMER'S INSTITUTE OF AMERICA; INC.;ALZHEIMERS INSTITUTE OF AMERICA
发明人:
MULLAN, MICHAEL, J,PARIS, DANIEL,IVEY, ROBERT, A
申请号：
NZ58472908
公开号：
NZ584729A
申请日:
2008.10.03
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is a pharmaceutical composition comprising optically active nilvadipine and a pharmaceutically acceptable carrier, the pharmaceutical composition comprising an excess of (-)-nilvadipine relative to (+)-nilvadipine, wherein the pharmaceutical composition is in a form suitable for parenteral, oral or interperitoneal administration. Also disclosed is The use of a therapeutically effective amount of enantiomerically-enriched (-)-nilvadipine in the manufacture of a composition for reducing the risk of cerebral amyloidogenic disease or condition resulting from A beta deposition, A beta neurotoxicity and microgliosis in an animal or human suffering from traumatic brain injury, wherein the composition is for administration following the acute head injury； or in an animal or human diagnosed with a risk for developing cerebral amyloidogenic disease or condition； or in an animal or human afflicted with a cerebral amyloidogenic disease or condition.
